Hemp Trading’s Panakeia CBG Variety Hits Canadian Market
rcfotostock | Adobe Stock

Hemp Trading’s Panakeia CBG Variety Hits Canadian Market

Panakeia will be the first CBG and feminized seed to be on the list of approved cultivars by Health Canada.

July 1, 2020

After closing a deal with U.S.-based Front Range Biosciences and Tesoro Genetics to sell its Panakeia hemp variety in December, Spanish company Hemp Trading is partnering with Cannabis Orchards to bring the high-CBG, zero-THC genetic to the Canadian hemp market.

The partnership, officially announced on June 25, will make Ottawa-based Cannabis Orchards the first Canadian company to bring to the hemp market a genetic that is THC-free, has a high CBG content (testing reports from Hemp Trading show Panakeia testing at 18% CBG) and that also is feminized.

“Through partnership with Hemp Trading, we will be introducing the first THC-free and CBG variety onto the list of approved cultivars of Health Canada, expected in fall 2020,” said Cannabis Orchard’s CEO Jamie Ghossein in a statement.

With an advertised cannabinoid content of 18% CBG and 0.00% THC, “Panakeia will be groundbreaking for the majority of cannabis users seeking health benefits,” Ghosseing continued. “In fact, according to government data, we know most Canadians are using cannabis for medicinal purposes. Yet, the Canadian offering of medicinal cannabis varieties with high CBD or CBG content is very poor.”

Hemp Trading markets Panakeia as a variety that will “never fail a field compliance test.” If that claim holds true, it may well present a solution to a problem that has plagued the hemp industry. In an email to Cannabis Business Times and Hemp Grower, Hemp Trading explained that it “made different screenings with some hemp varieties from different parts of the world,” before identifying “an anomalous individual with chemotype which produced big amounts of CBG with no CBD and THC.”

Hemp Trading also gene-tested its variety and “the results confirm this plant [does not have] the genes of [neither] CBD synthase [or] THC synthase. And that’s why Panakeia doesn’t produce any of these cannabinoids and accumulates CBG.”

The genetic’s high-CBG content also presents an opportunity for Cannabis Orchard’s team to conduct research on the potential health applications of the “grandfather cannabinoid,” including for cancer treatment.

SEE ALSO: CBG: A New(er) Option for Cancer Treatment?

“At Cannabis Orchards, we are constantly conducting research in developing innovative varieties intended as therapeutics,” Ghossein said. “Through this partnership we know we can offer something new, not only to cannabis users but potentially to patients in hospital. We are seeking to conduct pre-clinical trials with this variety and others developed through our breeding program and private-public partnerships with Canadian universities.”